1Medico-Surgical Intensive Care Unit, Hôpital Louis Mourier, AP-HP, Colombes, France.
2Department of Epidemiology and Clinical Research, Hôpital Louis Mourier, AP-HP, Colombes, France.
3Institut National de la Santé et de la Recherche Médicale (INSERM), IAME, UMR 1137, F-75018, Paris, France.
4Univ Paris Diderot, IAME, UMR 1137, Sorbonne Paris Cité, F-75018, Paris, France.
* See also p. 707.
Drs. Miguel-Montanes and Ricard designed the study and drafted the article. Drs. Hajage, Miguel-Montanes, and Ricard analyzed and interpreted the study data. Drs. Messika, Bertrand, Gaudry, Rafat, Labbé, Dufour, Jean-Baptiste, Bedet, and Miguel-Montanes collected the study data. Drs. Hajage, Messika, Bertrand, Gaudry, Rafat, Labbé, Dufour, Jean-Baptiste, Bedet, and Dreyfuss revised critically the article for significant intellectual content and approved its final version.
Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal’s website (http://journals.lww.com/ccmjournal).
Presented, in part, in abstract form at the 41st French Intensive Care Society International Congress, La Défense, France, July 15-17, 2013.
Dr. Gaudry received support for travel from Isis Medical. Dr. Dreyfuss provided expert testimony for Institut National de la Santé Et de la Recherche Médicale Transfert Initiatives (advice on possible development of a new agent against sepsis). Dr. Ricard received support from Fisher & Paykel (expenses to attend meetings have been covered by Fisher & Paykel, but without money directly paid to the author) and served as a board member for Covidien. The remaining authors have disclosed that they do not have any potential conflicts of interest.
For information regarding this article, E-mail: [email protected]